UBS Group
BBIO icon

UBS Group’s BridgeBio Pharma BBIO Stock Holding History

UBS Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131M Sell
1,757,152
-269,669
-13% -$18.9M 0.02% 940
2026
Q1 		$151M Buy
2,026,821
+151,156
+8% +$11M 0.02% 769
2025
Q4 		$143M Sell
1,875,665
-710,757
-27% -$46.7M 0.02% 765
2025
Q3 		$134M Sell
2,586,422
-226,077
-8% -$11M 0.02% 819
2025
Q2 		$121M Buy
2,812,499
+613,985
+28% +$22.3M 0.02% 828
2025
Q1 		$76M Buy
2,198,514
+358,659
+19% +$12.1M 0.01% 1115
2024
Q4 		$50.5M Buy
1,839,855
+753,062
+69% +$19.5M 0.01% 1456
2024
Q3 		$27.7M Sell
1,086,793
-5,521
-0.5% -$145K 0.01% 1572
2024
Q2 		$27.7M Sell
1,092,314
-7,232
-0.7% -$198K 0.01% 1426
2024
Q1 		$34M Buy
1,099,546
+114,036
+12% +$3.88M 0.01% 1304
2023
Q4 		$39.8M Buy
985,510
+832,940
+546% +$25M 0.01% 1117
2023
Q3 		$4.02M Sell
152,570
-10,011
-6% -$284K ﹤0.01% 2789
2023
Q2 		$2.8M Buy
162,581
+77,843
+92% +$1.17M ﹤0.01% 3200
2023
Q1 		$1.4M Sell
84,738
-275,140
-76% -$3.21M ﹤0.01% 3792
2022
Q4 		$2.74M Buy
359,878
+351,065
+3,983% +$3.36M ﹤0.01% 3065
2022
Q3 		$88K Sell
8,813
-212,264
-96% -$2.21M ﹤0.01% 5813
2022
Q2 		$2.01M Sell
221,077
-220,963
-50% -$1.85M ﹤0.01% 3147
2022
Q1 		$4.49M Buy
442,040
+377,753
+588% +$3.88M ﹤0.01% 2636
2021
Q4 		$1.07M Sell
64,287
-48,438
-43% -$2.05M ﹤0.01% 4327
2021
Q3 		$5.28M Buy
112,725
+90,850
+415% +$4.87M ﹤0.01% 2615
2021
Q2 		$1.33M Buy
21,875
+8,534
+64% +$487K ﹤0.01% 3937
2021
Q1 		$822K Sell
13,341
-5,777
-30% -$378K ﹤0.01% 4446
2020
Q4 		$1.36M Buy
19,118
+823
+4% +$39.7K ﹤0.01% 3757
2020
Q3 		$686K Sell
18,295
-1,049
-5% -$33K ﹤0.01% 3926
2020
Q2 		$631K Buy
19,344
+3,424
+22% +$104K ﹤0.01% 3958
2020
Q1 		$462K Sell
15,920
-2,121
-12% -$65.8K ﹤0.01% 4042
2019
Q4 		$632K Sell
18,041
-15,658
-46% -$434K ﹤0.01% 4629
2019
Q3 		$723K Buy
33,699
+33,099
+5,517% +$916K ﹤0.01% 4246
2019
Q2 		$16K Buy
+600
New +$16.4K ﹤0.01% 6756

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

UBS Group's BBIO Position: Q2 2026 in Review

UBS Group reduced its BridgeBio Pharma (BBIO) stake by 13% in Q2 2026, selling an estimated $18.9M and leaving 1,757,152 shares worth $131M. The position accounts for 0.02% of the portfolio, ranked #940.

UBS Group first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $151M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • UBS Group held 1,757,152 shares of BridgeBio Pharma worth $131M as of Q2 2026.
  • UBS Group sold 269,669 BridgeBio Pharma shares in Q2 2026, an estimated $18.9M.
  • BridgeBio Pharma made up 0.02% of UBS Group's portfolio in Q2 2026, its #940 holding.
  • UBS Group first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • UBS Group's BridgeBio Pharma position peaked at $151M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.